Experts Highlight How GLP-1s Have Revolutionized Management of T2D and Obesity

The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary.

Related Keywords

United States ,America ,Americans ,American ,Helfandc Glaxosmithkline ,Robert Zimmerman ,Diana Isaacs ,M Cecilia Lansang ,Yael Mauer ,Kevin Malloy ,Stacey Ehrenberg ,Masont Pregestational ,Study Group ,Astrazeneca ,Health Statistics ,Department Of Endocrinology At Cleveland Clinic ,Department Of Endocrinology ,Institute For Value ,National Center ,Life Sciences ,American Journal ,Cleveland Clinic ,Hispanic Black ,